• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sirtex SIR-spheres fail to meet primary endpoint in head-to-head trial

June 5, 2017 By Sarah Faulkner

Sirtex MedicalSirtex Medical (ASX:SRX) shares are down slightly today after its radioactive microspheres failed to meet the primary endpoint in a liver cancer trial.

The company’s SIR-Spheres Y-90 resin microspheres did not improve survival in patients with advanced hepatocellular carcinoma compared to a group treated with the current standard of care, sorafenib.

Data from the 360-patient trial were presented at the annual meeting for the American Society of Clinical Oncology.

“We found that the Asian patients with locally advanced HCC who were treated with Y-90 resin microspheres had a significantly better tumor response rate of 16.5% compared to 1.7% for sorafenib in the intent to treat, or ITT analysis, and 23.1% for SIRT compared to 1.9% in the treated population, which represents the patients who actually received their allocated treatment. They also experienced almost a 2-fold decrease in severe adverse events compared with those treated with sorafenib,” principal investigator Dr. Pierce Chow said in prepared remarks.

“The primary endpoint of the study, overall survival was not met. If you look at patients assigned to each therapy in the ITT, analysis, median survival in the Y-90 resin microspheres study arm was 8.84 versus 10.02 months for the sorafenib group. This difference is not statistically significant. However, this analysis does not take into account that more than a quarter of the patients who were scheduled to received Y-90 therapy actually didn’t receive treatment. If you look at the survival data based solely on those patients who actually received Y-90 resin microspheres, median OS was 11.3 months compared to 10.4 months for those treated with sorafenib, an opposite trend that is also not statistically significant.”

The company pointed out that the group treated with Y-90 microspheres had fewer side effects, but added that the incidence rate was not significantly different from the sorafenib group.

Sirtex said that patients who received Y-90 resin microspheres experienced additional treatment benefits, such as improved overall progression-free survival and overall time to progression.

These results are consistent with data from a 459-patient trial published in April this year. Survival differences between the 2 groups in that trial were also not significant.

In mid-May, SRX shares tumbled more than 25% after data from a trial showed that the Y-90 microspheres had no effect in improving survival in patients with colorectal cancer.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Wall Street Beat Tagged With: Sirtex Medical

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS